Standout Papers
Citation Impact
Citing Papers
Activating Mutations in PIK3CB Confer Resistance to PI3K Inhibition and Define a Novel Oncogenic Role for p110β
2016
Intermittent Administration of MEK Inhibitor GDC-0973 plus PI3K Inhibitor GDC-0941 Triggers Robust Apoptosis and Tumor Growth Inhibition
2011
Functional Characterization of an Isoform-Selective Inhibitor of PI3K-p110β as a Potential Anticancer Agent
2012
DAXX / ATRX , MEN1 , and mTOR Pathway Genes Are Frequently Altered in Pancreatic Neuroendocrine Tumors
2011 Science
Protein characterization of Saccharomyces cerevisiae RNA polymerase II after in vivo cross-linking
2007 StandoutNobel
Phase I Dose-Escalation Study of Taselisib, an Oral PI3K Inhibitor, in Patients with Advanced Solid Tumors
2017
PIK3CA Mutation H1047R Is Associated with Response to PI3K/AKT/mTOR Signaling Pathway Inhibitors in Early-Phase Clinical Trials
2012
A First-in-Human, Phase I, Dose-Escalation Study of TAK-117, a Selective PI3Kα Isoform Inhibitor, in Patients with Advanced Solid Malignancies
2017
Structural Basis of Transcription: Backtracked RNA Polymerase II at 3.4 Angstrom Resolution
2009 StandoutScienceNobel
Combined Inhibition of Both p110α and p110β Isoforms of Phosphatidylinositol 3-Kinase Is Required for Sustained Therapeutic Effect in PTEN-Deficient, ER+ Breast Cancer
2016
Alpelisib for PIK3CA -Mutated, Hormone Receptor–Positive Advanced Breast Cancer
2019 Standout
Functional Genomic Analysis of RNA Interference in C. elegans
2005 StandoutScienceNobel
Nascent RNA Sequencing Reveals Widespread Pausing and Divergent Initiation at Human Promoters
2008 StandoutScience
First-in-Human Pharmacokinetic and Pharmacodynamic Study of the Dual m-TORC 1/2 Inhibitor AZD2014
2015
TORC1 Suppression Predicts Responsiveness to RAF and MEK Inhibition in BRAF- Mutant Melanoma
2013
An enzymatic toolkit for selective proteolysis, detection, and visualization of mucin-domain glycoproteins
2020 StandoutNobel
PTEN-Deficient Tumors Depend on AKT2 for Maintenance and Survival
2014
Antitumor Efficacy of PKI-587, a Highly Potent Dual PI3K/mTOR Kinase Inhibitor
2011
A Multicenter Phase I Trial of PX-866, an Oral Irreversible Phosphatidylinositol 3-Kinase Inhibitor, in Patients with Advanced Solid Tumors
2012
Regulation of phosphoinositide 3-kinase expression in health and disease
2009
Comprehensive molecular portraits of human breast tumours
2012 StandoutNature
Measurement of PIP3 Levels Reveals an Unexpected Role for p110β in Early Adaptive Responses to p110α-Specific Inhibitors in Luminal Breast Cancer
2014
Hallmarks of Cancer: The Next Generation
2011 Standout
A Visualizable Chain‐Terminating Inhibitor of Glycosaminoglycan Biosynthesis in Developing Zebrafish
2014 StandoutNobel
The hVps34‐ SGK 3 pathway alleviates sustained PI3K/Akt inhibition by stimulating mTORC 1 and tumour growth
2016
Combination of Antibody That Inhibits Ligand-Independent HER3 Dimerization and a p110α Inhibitor Potently Blocks PI3K Signaling and Growth of HER2+ Breast Cancers
2013
Triple-Negative Breast Cancer
2010 Standout
The Skp2-SCF E3 Ligase Regulates Akt Ubiquitination, Glycolysis, Herceptin Sensitivity, and Tumorigenesis
2012
The PI3K/AKT Pathway as a Target for Cancer Treatment
2015
Smarter drugs emerging in pancreatic cancer therapy
2014
The Regulation of Class IA PI 3-Kinases by Inter-Subunit Interactions
2010
Chapter 2 PI3K/PTEN Signaling in Angiogenesis and Tumorigenesis
2009
Combined Vemurafenib and Cobimetinib in BRAF -Mutated Melanoma
2014 Standout
Gene loops juxtapose promoters and terminators in yeast
2004
The contribution of gene expression profiling to breast cancer classification, prognostication and prediction: a retrospective of the last decade
2009
mTOR Signaling in Growth Control and Disease
2012 Standout
MYC on the Path to Cancer
2012 Standout
A view on drug resistance in cancer
2019 StandoutNature
Akt and mTOR in B Cell Activation and Differentiation
2012
Reaching for high-hanging fruit in drug discovery at protein–protein interfaces
2007 StandoutNature
Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors
2012
Pten Positively Regulates Brown Adipose Function, Energy Expenditure, and Longevity
2012
Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy
2011
Posttranslational regulation of Akt in human cancer
2014
Molecular mechanisms of epithelial–mesenchymal transition
2014 Standout
Ovarian cancer
2014 Standout
New perspectives on connecting messenger RNA 3′ end formation to transcription
2004
Early Formation of mRNP
2003 StandoutNobel
Synergy in activating class I PI3Ks
2015
Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer
2015 StandoutNature
Cancer Epigenetics: From Mechanism to Therapy
2012 Standout
Links between metabolism and cancer
2012
Autophagy: Renovation of Cells and Tissues
2011 Standout
The complex language of chromatin regulation during transcription
2007 StandoutNature
What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer
2013 StandoutNobel
Hypoxia and the extracellular matrix: drivers of tumour metastasis
2014 StandoutNobel
The Histone Chaperone Spt6 Is Required for Activation-induced Cytidine Deaminase Target Determination through H3K4me3 Regulation
2012 StandoutNobel
Emergence of the Phosphoinositide 3-Kinase-Akt- Mammalian Target of Rapamycin Axis in Transforming Growth Factor-β-Induced Epithelial-Mesenchymal Transition
2010
A Chromatin Landmark and Transcription Initiation at Most Promoters in Human Cells
2007 Standout
Identification and structure–activity relationship of 2-morpholino 6-(3-hydroxyphenyl) pyrimidines, a class of potent and selective PI3 kinase inhibitors
2010
Kinase and BET Inhibitors Together Clamp Inhibition of PI3K Signaling and Overcome Resistance to Therapy
2015
Identifying functional modules in the physical interactome of Saccharomyces cerevisiae
2007
Tumour heterogeneity and cancer cell plasticity
2013 StandoutNature
Evaluation of Factors Related to Late Recurrence - Later than 10 Years after the Initial Treatment - in Primary Breast Cancer
2013 Standout
Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092
2015
Suppression of inflammation by a synthetic histone mimic
2010 StandoutNatureNobel
Dynamic Lysine Methylation on Histone H3 Defines the Regulatory Phase of Gene Transcription
2005
Programmed Cell Senescence during Mammalian Embryonic Development
2013 Standout
PI3K and MEK inhibitor combinations: examining the evidence in selected tumor types
2013
The causes and consequences of genetic heterogeneity in cancer evolution
2013 StandoutNature
A chemical-genetic screen reveals a mechanism of resistance to PI3K inhibitors in cancer
2011
CDK 4/6 Inhibitors Sensitize PIK3CA Mutant Breast Cancer to PI3K Inhibitors
2014
A metabolic labeling approach for glycoproteomic analysis reveals altered glycoprotein expression upon GALNT3 knockdown in ovarian cancer cells
2016 StandoutNobel
Autophagy as a target for anticancer therapy
2011
PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting
2014
Understanding the Intersections between Metabolism and Cancer Biology
2017 Standout
The PtdIns(3,4)P2 phosphatase INPP4A is a suppressor of excitotoxic neuronal death
2010 StandoutNatureNobel
Transitions in RNA polymerase II elongation complexes at the 3′ ends of genes
2004
AKT/PKB Signaling: Navigating the Network
2017 Standout
Elongation by RNA polymerase II: the short and long of it
2004
MUC1-C oncoprotein as a target in breast cancer: activation of signaling pathways and therapeutic approaches
2012
The Hallmarks of Aging
2013 Standout
CRISPR-Based Technologies for the Manipulation of Eukaryotic Genomes
2016 Standout
The PI3K Pathway in Human Disease
2017 Standout
3′‐end formation signals modulate the association of genes with the nuclear periphery as well as mRNP dot formation
2006 StandoutNobel
Glutamine Deprivation Induces Abortive S-Phase Rescued by Deoxyribonucleotides in K-Ras Transformed Fibroblasts
2009
A 3D Map of the Human Genome at Kilobase Resolution Reveals Principles of Chromatin Looping
2014 Standout
Molecular Architecture of the Human Pre-mRNA 3′ Processing Complex
2009 StandoutNobel
CTCF: Master Weaver of the Genome
2009 Standout
The phosphoinositide 3-kinase pathway and therapy resistance in cancer
2015
Biochemical analysis of TREX complex recruitment to intronless and intron‐containing yeast genes
2004 StandoutNobel
Emerging targeted agents in metastatic breast cancer
2013
Pharmacological inhibition of DNA-PK stimulates Cas9-mediated genome editing
2015
Autochthonous tumors driven by Rb1 loss have an ongoing requirement for the RBP2 histone demethylase
2018 StandoutNobel
Synthesis and in Vitro and in Vivo Evaluation of Phosphoinositide-3-kinase Inhibitors
2010
Accumulation of the FACT complex, as well as histone H3.3, serves as a target marker for somatic hypermutation
2013 StandoutNobel
Inhibition of class IA PI3K enzymes in non-small cell lung cancer cells uncovers functional compensation among isoforms
2015
Inositol polyphosphate 4-phosphatase II regulates PI3K/Akt signaling and is lost in human basal-like breast cancers
2010
Elevated SGK1 predicts resistance of breast cancer cells to Akt inhibitors
2013
The PI3K Isoforms p110α and p110δ Are Essential for Pre–B Cell Receptor Signaling and B Cell Development
2010
PI3K isoform dependence of PTEN-deficient tumors can be altered by the genetic context
2014
Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas
2016 Standout
Long‐term p110α PI3K inactivation exerts a beneficial effect on metabolism
2013
Tumor Suppression by LKB1: SIK-ness Prevents Metastasis
2009
Metabolic reprogramming and cancer progression
2020 StandoutScience
Biology and targeting of the Jumonji-domain histone demethylase family in childhood neoplasia: a preclinical overview
2019
Cancer Genome Landscapes
2013 StandoutScience
Signaling by the Phosphoinositide 3-Kinase Family in Immune Cells
2013
Simultaneous precise editing of multiple genes in human cells
2019 StandoutNobel
The Evolution of Protein Kinase Inhibitors from Antagonists to Agonists of Cellular Signaling
2011
mTORC1-Activated S6K1 Phosphorylates Rictor on Threonine 1135 and Regulates mTORC2 Signaling
2009
Molecular Regulation of H3K4 Trimethylation by Wdr82, a Component of Human Set1/COMPASS
2008
PI3K pathway regulates ER-dependent transcription in breast cancer through the epigenetic regulator KMT2D
2017 Science
Phosphatidylinositol 3-Kinase, Growth Disorders, and Cancer
2018
Circumventing Cancer Drug Resistance in the Era of Personalized Medicine
2012
Chemical Glycoproteomics
2016 StandoutNobel
Works of Hailing Cheng being referenced
The C-terminal Domains of Vertebrate CstF-64 and Its Yeast Orthologue Rna15 Form a New Structure Critical for mRNA 3′-End Processing
2006
The p110α and p110β isoforms of PI3K play divergent roles in mammary gland development and tumorigenesis
2012
Oncogenic PIK3CA-driven mammary tumors frequently recur via PI3K pathway–dependent and PI3K pathway–independent mechanisms
2011
Targeting the phosphoinositide 3-kinase pathway in cancer
2009 Standout
PI3K/AKT Signaling Regulates H3K4 Methylation in Breast Cancer
2016
Functional interactions between the transcription and mRNA 3′ end processing machineries mediated by Ssu72 and Sub1
2003
Effective use of PI3K inhibitor BKM120 and PARP inhibitor Olaparib to treat PIK3CA mutant ovarian cancer
2016
Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapies
2013
The Essential WD Repeat Protein Swd2 Has Dual Functions in RNA Polymerase II Transcription Termination and Lysine 4 Methylation of Histone H3
2004
The p110α isoform of PI3K is essential for proper growth factor signaling and oncogenic transformation
2006
SIK1 Couples LKB1 to p53-Dependent Anoikis and Suppresses Metastasis
2009